Page last updated: 2024-12-08

vintriptol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID10463634
CHEMBL ID2103948
MeSH IDM0143793

Synonyms (14)

Synonym
(23(s))-4-deacetyl-3-((1-carboxy-2-indol-3-ylethyl)carbamoyl)-3-de(methoxycarbonyl)vincaleukoblastine, ethyl ester
vincaleukoblastine, o(sup 4)-deacetyl-3-de(methoxycarbonyl)-3-(((2-ethoxy-1-(1h-indol-3-ylmethyl)-2-oxoethyl)amino)carbonyl)-, (23(s))-
vintriptolum [latin]
vintriptol [inn]
v-l-trp-oet
4-deacetyl-3-(((s)-1-(ethoxycarbonyl)-2-(3-indolyl)ethyl)aminocarbonyl)-3-de(methoxycarbonyl)vincaleukoblastin
vintriptol
vintriptolum
unii-4gz191298d
vinblastine tryptophan ester
4gz191298d ,
CHEMBL2103948
Q27259575
methyl (13s,15r,17s)-13-[(1r,9r,10s,11r,12r,19r)-10-[[(2s)-1-ethoxy-3-(1h-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]-12-ethyl-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-17-hydroxy-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The applicability of the assay was demonstrated in a pharmacokinetic study with eight cancer patients who received 45 or 50 mg/m2 vintriptol in a phase I study."( High-performance liquid chromatographic bio-analysis and preliminary pharmacokinetics of the experimental antitumour drug vintriptol.
Beijnen, JH; Nooyen, WJ; Rao, KS; ten Bokkel Huinink, WW; van der Woude, HR; van Tellingen, O, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's5 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]